Rezultati - Wechalekar, Ashutosh
- Showing 1 - 20 results of 55
- Go to Next Page
-
1
The Evolving Epidemiology of Amyloidosis od Wechalekar, Ashutosh D.
Izdano 2021Text -
2
-
3
-
4
-
5
-
6
Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of c... od Wechalekar, Ashutosh D., Gillmore, Julian D., Wassef, Nancy, Lachmann, Helen J., Whelan, Carol, Hawkins, Philip N.
Izdano 2011Text -
7
-
8
-
9
Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis - a 2 year follow-up study od Banypersad, Sanjay M, Fontana, Marianna, Maestrini, Viviana, Sado, Daniel, White, Steven K, Treibel, Thomas A, Lachmann, Helen, Wechalekar, Ashutosh, Hawkins, Philip N, Moon, James
Izdano 2014Text -
10
Diagnosis, Pathogenesis, Treatment, and Prognosis of Hereditary Fibrinogen Aα-Chain Amyloidosis od Gillmore, Julian D., Lachmann, Helen J., Rowczenio, Dorota, Gilbertson, Janet A., Zeng, Cai-Hong, Liu, Zhi-Hong, Li, Lei-Shi, Wechalekar, Ashutosh, Hawkins, Philip N.
Izdano 2009Text -
11
A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis od Sharpley, Faye A., Manwani, Richa, Mahmood, Shameem, Sachchithanantham, Sajitha, Lachmann, Helen J., Gillmore, Julian D., Whelan, Carol J., Fontana, Marianna, Hawkins, Philip N., Wechalekar, Ashutosh D.
Izdano 2019Text -
12
Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis od Sachchithanantham, Sajitha, Offer, Mark, Venner, Christopher, Mahmood, Shameem A., Foard, Darren, Rannigan, Lisa, Lane, Thirusha, Gillmore, Julian D., Lachmann, Helen J., Hawkins, Philip N., Wechalekar, Ashutosh D.
Izdano 2015Text -
13
Deferred autologous stem cell transplantation in systemic AL amyloidosis od Manwani, Richa, Hegenbart, Ute, Mahmood, Shameem, Sachchithanantham, Sajitha, Kyriakou, Charalampia, Yong, Kwee, Popat, Rakesh, Rabin, Neil, Whelan, Carol, Dittrich, Tobias, Kimmich, Christoph, Hawkins, Philip, Schönland, Stefan, Wechalekar, Ashutosh
Izdano 2018Text -
14
Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria od Sharpley, Faye A., Fontana, Marianna, Martinez-Naharro, Ana, Manwani, Richa, Mahmood, Shameem, Sachchithanantham, Sajitha, Lachmann, Helen J., Gillmore, Julian D., Whelan, Carol J., Hawkins, Philip N., Wechalekar, Ashutosh D.
Izdano 2020Text -
15
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID‐19 pandemic od Kastritis, Efstathios, Wechalekar, Ashutosh, Schönland, Stefan, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Minnema, Monique, Roussel, Murielle, Jaccard, Arnaud, Hegenbart, Ute, Kumar, Shaji, Cibeira, Maria T., Blade, Joan, Dimopoulos, Meletios A.
Izdano 2020Text -
16
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis od Ravichandran, Sriram, Law, Steven, Mahmood, Shameem, Wisniowski, Brenden, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Hawkins, Philip N., Wechalekar, Ashutosh D.
Izdano 2022Text -
17
Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis od Dungu, Jason, Whelan, Carol J, Gibbs, Simon D, Pinney, Jennifer H, Banypersad, Sanjay M, Venner, Christopher P, Lachmann, Helen J, Wechalekar, Ashutosh, Gillmore, Julian D, Hawkins, Philip N, Anderson, Lisa
Izdano 2012Text -
18
Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis od Manwani, Richa, Foard, Darren, Mahmood, Shameem, Sachchithanantham, Sajitha, Lane, Thirusha, Quarta, Cristina, Youngstein, Taryn, Rezk, Tamer, Lachmann, Helen J, Gillmore, Julian D., Fontana, Marianna, Whelan, Carol, Hawkins, Philip N., Wechalekar, Ashutosh
Izdano 2018Text -
19
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib od Ravichandran, Sriram, Cohen, Oliver C., Law, Steven, Foard, Darren, Fontana, Marianna, Martinez-Naharro, Ana, Whelan, Carol, Gillmore, Julian D., Lachmann, Helen J., Sachchithanantham, Sajitha, Mahmood, Shameem, Hawkins, Philip N., Wechalekar, Ashutosh D.
Izdano 2021Text -
20
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis od Rezk, Tamer, Gilbertson, Janet A, Mangione, P Patrizia, Rowczenio, Dorota, Rendell, Nigel B, Canetti, Diana, Lachmann, Helen J, Wechalekar, Ashutosh D, Bass, Paul, Hawkins, Philip N, Bellotti, Vittorio, Taylor, Graham W, Gillmore, Julian D
Izdano 2019Text